Vanderschaeghe D, Szekrényes Á, Wenz C, Gassman M, Naik N, Bynum M, Yin H, Delanghe J, Guttman A, Callewaert N
Analytical Chemistry (2010) vol.82 7408-7415
Developed 3 h procedure for preparing serum N-glycans and labelling them with 8-aminopyrene-1,3,6-trisulfonic acid. This followed by successful analysis via capillary electrophoresis on three microfluidics-based platforms: MCE 202 MultiNa, 2100 Bioanalyzer and a modified prototype of the eGene system. This GlycoHepatoTest allows follow-up liver fibrosis patients from an early stage.
Callewaert N, Vlierberghe H, Hecke A, Laroy W, Delanghe J, Contreras R
Nature Medicine (2004) vol.10 chapter 4 429-434
Technologies based on DNA sequencer/fragment analysers generated a N-glycan serum protein profile in liver disease patients. This yielded a biomarker that distinguishes compensated cirrhotic from noncirrhotic chronic liver disease with high specificity and sensitivity. Especially when combined with Fibrotest biomarker.
Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Hecke A, Delanghe J, Callewaert N
MCP Papers: Molecullar and Cellular Proteomics (2009) vol.8.5 986-994
Investigation into serum N-glycome’s potential as a biomarker via 96-well plate-based serum N-glycome comics to be used in capillary electrophoresis-based DNA sequencers. A blinded study of 376 chronic hepatitis C virus patients found the ratios of two N-glycans (GlycoFibroTest) correlates with the histological fibrosis stage. Affinity chromatography was used to deplete partially determining GlycoFibroTest.
Laroy W, Contreras R, Callewaert N
Nature Protocols (2006) vol.1 chapter 1 397-405
An offered detailed protocol for the analysis of protein-linked glycans on DNA sequencing equipment. The protocol utilizes mutlticapillary DNA sequencers, resolving isobaric glycan stereoisomers and facilitates two-dimensional profiling or MS analysis of particular compounds.
Vanderschaeghe D, Festjens N, Delanghe H, Callewaert N
Biological Chemistry (2010) vol.391 149-161
Review on glycomics research and the highlights of glycan profiling tools between 2005 and 2010. The review focuses mainly on capillary electrophoresis, liquid chromatography, mass spectrometry and lectin microarrays.
Blomme B, Francque S, Trépo E, Libbrecth L, Vanderschaeghe D, Verrijken A, Pattyn P, Nieuwhenhove Y, Putte D, Geerts A, Colle I, Delanghe J, Moreno C, Gaal L, Callewaert N, Vlierberghe H
Elsevier: Digestive and Liver Disease (2012) vol.44 315-322
N-glycosylation of serum proteins used to identify NASH biomarker by assessing patterns using DNA sequencer-assiosted flrophore-assisted capillary electrophoresis and histology. The glycomarker recognized liver inflammation in obese individuals and can differentiate between steatosis and NASH.
Verhelst X, Vanderschaeghe D, Castéra L, Geerts A, Goutté N, Francoz C, Durand F, Callewaert N, Vlierberghe H
Journal of Hepatology (2015) vol.62 supp. 2 365-369
132 blood samples of cirrhotic patients, majorly (70%) caused by HCV infections, were analysed. There was a significant increase in the mean baseline GlycoCirrhoTest value in the patients who developed HCC during follow up (p<0.001) compared to those that did not. Concluded as a useful biomarker for identification of high risk HCC individuals with stratified cirrhosis.
Blomme B, Steenkiste C, Callewaert N, Vlierberghe H
Journal of Hepatology (2009) vol.50 592-603
This review explores non-invasive liver analysis via usage of protein glycolysation as pathogenic biomarkers. Individual liver diseases have specific biomarkers, hyperfucosylation, increased branching and bisecting N-acetylgucosamine modification continuously reappear in all of them. Analysis at mRNAand protein level confirms their altered status in liver pathology.
Fujii H, Kawada N
Journal of Gastroenterology (2012) vol.47 issue 3 215-225
Summary of biochemical and physical changes that leads to the silent symptoms of NAFLD and NASH. Information on the basic pathogenesis of Nash with a focus on inflammation and fibrosis.
Leal O, Mafra D
Clinica Chimica Acta (2013) vol.419 87-94
The review focuses on obesity specific-adipokine profiles and the role of some adipokines in obesity related metabolic disorders. Due to obesity’s link to increased adipose tissue, it believes adipokines play an important role in obesity related diseases such as insulin resistance, inflammation, hypertension, cardiovascular risk and metabolic disorders.
Blomme B, Steenkiste C, Grassi P, Haslam S, Dell A, Callewaert N, Vlierberghe H
American Journal of Physiology: Gastrointestinal and Liver Physiology (2011) vol.300 833-842
Induction of inflammatory cases in B cell-deficient and wild-type mice to study the cells impact in chronic liver disease. It further outlines the impact of IgG glycosylation and fibrogenesis in B cell-deficient mice.
Arnold N, Saldova R, Hamid M, Rudd M
Proteomics (2008) vol.8 no. 16 3284–3293
In this review, the glycoproteins which display glycan epitopes, the glycosyl transferases which can generate them, their potential functions and their use as biomarkers are evaluated in link with chronic inflammatory diseases and cancers.
Kam R, Poon T, Chan H, Wong N, Hui A, Sung J
Hong Kong Medical Journal (2009) vol.15 supp. 8 42-44
Research concerning the establishment of high-throughput assay for quantitative profiling of N-glycans attached to serum glycoproteins, identification a panel of serum N-glycans as potential biomarkers for diagnosing liver cirrhosis and fibrosis and glycan peaks being able to detect these diseases with high accuracy.
Nagels B, Damme E, Callewaert N, Weterings K
Plant Science (2012) vol.185 161-168
Expression of human acetylglucosaminyltransferase genes (GnT – IV and GnT – V) in fast cycling model plant Arabidopsis thaliana to synthesize tri-antennary N-glycans.
Wieckowska A, Feldstein A
Seminars in Liver Disease (2008) vol.28 386-395
A review providing concise overview of the role of liver biopsy versus noninvasive diagnostic tools for the differentiation of fatty liver from non-alcoholic steatohepatitis as well as for the determination of presence and extent of fibrosis. Focuses mainly on currently available clinical practices and touches briefly on future markers under investigation.
Vanhooren V, Dewaele S, Kuro-o M, Taniguchi N, Dolle L, Grunsven L, Makrantonaki E, Zouboulis C, Chen C, Libert C
Aging Cell (2011) vol.10 issue 6 1056-1066
Age-related changes in NGA2F, NA2 and NA2F in mice serum and its connection to the expression of FUT8. Lightly touches on N-glycan changes in mice serum based on calorie restriction.
Wang Y, Fukada T, Isaji T, Lu J, Gu W, Lee H, Ohkubo Y,Kamada Y, Taniguchi N, Miyoshi E, Gu J
Scientific Report (2015) vol.5 article nr. 8264
Ji E, Hwang H, Park G, Lee J, Lee H, Choi N, Jeong H, Kim K, Kim J, Lee S, Ahn Y
Analytical and Bioanalytical Chemistry (2016) vol.408 issue 27 7761-7774
Fucosylated N-glycopeptides identified in liver-secreted proteins from HCC plasma in a site-specific analysis.
Takahasi M, Kuroki Y, Ohtsubo K, Taniguchi N
Carbohydrate Research (2009) vol.344 issue 12 1387-1390
Artifical alteration of cloned glycosyltransferases, with a focus on Fut9 and GnT-III involved in biosynthesis of N-glycan branching, adhesion of molecules and cell surface receptors.
Miwa H, Kobe W, Fine E, Giricz O, Kenny P, Stanley P
Glycobiology (2013) vol.23 issue 12 1477-1490
Lightly touches on N-acetylglucosaminyl and effect of certain complex N-glycans in cancerous tissue in relation to bisection.
Xu Q, Isaji T, Lu Y, Gu W, Kondo M, Fukada T, Du Y, Gu J
The Journal of Biological Chemistry (2012) vol.287 issue 20 16563-16574
GnT-III influenced EMT-like changes through not only prolongation of E-cadherin turnover but also suppression of β-catenin·p-Smad complex formation. GnT-III plays important roles in TGF-β-induced EMT-like changes.